Aska Pharmaceutical Holdings Co.,Ltd. (4886.T) Stock
Aska Pharmaceutical Holdings Co.,Ltd.

Company profile
Its largest business segment, Pharmaceuticals Business, brought in 88% of segment revenue in fiscal year 2024. Aska Pharmaceutical Holdings reports about 1,611 full-time employees.
What stands out
- Revenue in fiscal year 2025 was the highest of the last 4 fiscal years.
Figures from company filings; latest fiscal year ended March 31, 2026.
About Aska Pharmaceutical Holdings Co.,Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and other businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the areas of internal medicine, obstetrics and gynecology, and urology; and research, manufactures, imports, exports, and sells veterinary medicines and medical devices, feed and feed additives, reagents, agrochemicals, industrial chemicals, hygiene products, and food products and their raw materials. It is also involved in the clinical examination and biological testing activities; engages in the manufacturing, sales, import, and distribution of prescription drugs, over-the-counter drugs, health foods, and other products; and offers quasi-drugs, food supplements, and medical devices. The company was founded in 1920 and is headquartered in Tokyo, Japan.
Largest shareholders
- Dalton Investments, Inc.10.03%
- Rising Sun Management Ltd.8.28%
- Takeda Pharmaceutical Company Limited7.67%
- Zeria Pharmaceutical Co., Ltd.6.53%
- Mitsubishi Ufj Financial Group, Inc.3.82%
Share of the company, as of September 25, 2026
Leadership
- Sohta Yamaguchi — President & Representative Director, 42
- Takashi Yamaguchi — Representative Director & Chairman of the Board, 73
- Atsushi Maruo — Senior Managing Director & Representative Director, 66
- Tomoyuki Hatakeyama — Director of Finance & Accounting Dept., Group Bus. Mgmt Div. and Manager of Accounting Section
- Fumiyoshi Yamaguchi — Managing Executive Officer & Director, 39
What is Aska Pharmaceutical Holdings's largest business segment?
Pharmaceuticals Business, with 56.66 billion JPY or 88% of segment revenue in fiscal year 2024. Next: Animal Health Business (11%) and Other (1%).
What companies are similar to Aska Pharmaceutical Holdings?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Mochida Pharmaceutical Co., Ltd. (4534.T), Zeria Pharmaceutical Co., Ltd. (4559.T), Kyorin Pharmaceutical Co., Ltd. (4569.T), Fuji Pharma Co., Ltd. (4554.T).
How has Aska Pharmaceutical Holdings' revenue changed over the last 4 fiscal years?
Revenue by fiscal year: FY2022, 56.61 billion JPY; FY2023, 60.46 billion JPY; FY2024, 62.84 billion JPY; FY2025, 64.14 billion JPY.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Aska Pharmaceutical Holdings Co.,Ltd. (4886.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4886.T